Dovobet ® is a compounded combination of calcipotriol [also calcipotriene] and betamethasone diproprionate, and is used for psoriasis vulgaris ... option in the treatment of psoriasis.

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

No local treatment except white vaseline was used ... Eleven patients with severe and persistent psoriasis vulgaris were maintained on a restricted diet allowing 150 to 300 international units ...

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2 ...

This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...

is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA). Biocon Biologics Ltd previously notified the stock exchanges on August 29, 2024, that the company had entered ...

Arctic therapeutics raises funding from EIC Fund, Kaldbakur, and Sanos Group to advance its dementia treatment, AT-001, and acne drug, AT-004. The company aims to transform the treatment landscape for ...

According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success ... inflammatory bowel disease (IBD); KBLP-002 program for the treatment of asthma ...

According to GlobalData, Phase III drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 82% phase transition success ... ESK-001 is under development for the treatment of systemic lupus ...